Results 201 to 210 of about 275,402 (290)

Real-world outcomes and toxicities of CAR-T in relapsed/refractory follicular lymphoma: a multicenter cohort study. [PDF]

Blood Adv
Sharp J, Strati P, Bhatta S, Huang JJ, Thomas C, Elghawy O, Reef D, Gorzewski A, Wang J, Shouse G, Reinert C, Teferra A, Velez ET, Pelcovits A, Ollila T, Clark W, Yazbeck V, Maakaron J, Kamdar M, Fitzgerald L, Danilov A, Karmali R, Grover NS, Barta SK, Voorhees TJ, Chen AI, Shadman M, Ahmed S, Epperla N.   +28 more
europepmc   +1 more source

Relative Dose Intensity and Survival Outcomes in Older Adults With Lymphoma: A Single‐Center Retrospective Analysis

Journal of General and Family Medicine, Volume 27, Issue 5, September 2026.
ABSTRACT Background Treatment intensity in older adults with lymphoma is often reduced because of frailty, comorbidities, and poor performance status (PS). Whether chronological age or delivered treatment intensity better predicts outcomes remains unclear.
Akira Mochizuki, Shotaro Hagiwara
wiley   +1 more source

Impact of marital status on survival in patients with follicular lymphoma. [PDF]

Ann Hematol
He S, Song H, Zuo W, Liu S, Fang X, Li X.   +5 more
europepmc   +1 more source

Cost-Effectiveness of Epcoritamab Plus Lenalidomide and Rituximab Versus Lenalidomide and Rituximab for Relapsed/Refractory Follicular Lymphoma: A US Payer Perspective. [PDF]

Hematol Oncol
He Y, Wu M, Li A, Yi Y, Wan X.
europepmc   +1 more source

Artificial Intelligence Integration With Nanotechnology for Cancer Therapy

MedComm, Volume 7, Issue 9, September 2026.
AI‐enabled nanotechnology provides a continuous learning framework for cancer therapy by integrating nanomaterial design, biological interactions, tumor delivery, clinical data, and therapeutic feedback to support predictive design, patient‐aware optimization, and improved translational decision‐making.
Shengbin Liu, Zhi Liu, Haixing Shi, Chengyi Wei, Ruijie Zhang, Xiangrong Song   +5 more
wiley   +1 more source

Immune Myositis Complicating Follicular Lymphoma: Case Report. [PDF]

Reports (MDPI)
Zacharia GS, Ajai Mokan Dasan SL, Iwuaba C.   +2 more
europepmc   +1 more source

Immune Checkpoint Inhibitors in Cancer Therapy: Clinical Landscape, Resistance Mechanisms, and Therapeutic Innovations

MedComm – Oncology, Volume 5, Issue 3, September 2026.
The up‐to‐date clinical progress of immune checkpoint inhibitor (ICI) therapy in solid tumors, specifically the combinational regimens between ICIs and other treatment strategies, the mechanisms underlying primary and acquired resistance, and mechanism‐matched strategies to improve clinical outcomes are synthesized in this review.
Qiongyu Zhang, Zhi Qin, Caijuan Guo
wiley   +1 more source

Nontranslocation follicular lymphoma mimicking infectious mononucleosis: a diagnostic challenge in a 39-year-old male. [PDF]

Oxf Med Case Reports
Barsh E, Keeling J, Pang CS, Sattler R, Feustel K, Enurah A.   +5 more
europepmc   +1 more source

Follicular lymphoma genomics

HemaSphere, 2019
Kumar, E, Okosun, J
openaire   +4 more sources

Cancer heterogeneity explored through immune cell deconvolution of the tumor microenvironment

Quantitative Biology, Volume 14, Issue 3, September 2026.
Abstract Cancer is a highly heterogeneous disease, characterized by significant variability across multiple dimensions. This diversity has been extensively studied from various perspectives. In this study, we aim to examine cancer heterogeneity through the lens of immune cell composition within the tumor microenvironment.
Limin Jiang, Chung‐I Li, Rui Xin, Jijun Tang, Yan Guo   +4 more
wiley   +1 more source